title: Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.
abstract: BACKGROUND
  The broadly neutralizing recombinant human HIV-1 antibodies 4E10, 2F5 and Igh1b12 are reported to have autoreactive potential, which is significant for HIV-1 vaccine development and passive immunotherapy using these antibodies.
  
  
  OBJECTIVE
  To investigate the clinical relevance of these findings in subjects receiving passive immunotherapy with these antibodies.
  
  
  METHODS
  Four types of investigations were performed: (1) Investigation of clotting parameters in an ongoing clinical study with 4E10, 2F5 and 2G12. (2) Mixing experiments of pooled plasma with the same antibodies. (3) Retrospective analysis of serum from patients who received passive immunotherapy with 4E10, 2F5 and 2G12 either alone or in combination. (4) Assessment of clinical safety data obtained after 418 infusions with these antibodies.
  
  
  RESULTS
  Standard clinical assays confirmed that 4E10 showed low-level cross-reactivity with cardiolipin, while previously reported cardiolipin cross-reactivity for 2F5 could not be confirmed. High serum titers of 4E10 induced mild prolongation of the activated partial thromboplastin time, which resolved with the wash out of 4E10. Neither 2F5 nor 2G12 affected coagulation. Repeated high-dose infusions of the monoclonal antibody combination were well tolerated with no incidence for thrombotic complications after 418 infusions in 39 subjects.
  
  
  CONCLUSIONS
  Monoclonal antibody 4E10 but not 2F5 or 2G12 showed autoreactive binding specificities. Infusion of 4E10 resulted in transient low anticardiolipin titers. Although an increased thromboembolic risk cannot definitely be excluded, this risk appears to be low and likely depend on underlying disorders.
authors: Polymun Scientific, Vienna bImmunology Outpatient Clinic, Vienna, Austria. Brigitta.Vcelar@boku.ac.at
authors: Brigitta
authors: B
authors: Vcelar
authors: Gabriela
authors: G
authors: Stiegler
authors: Hermann M
authors: HM
authors: Wolf
authors: Wolfgang
authors: W
authors: Muntean
authors: Bettina
authors: B
authors: Leschnik
authors: Saurabh
authors: S
authors: Mehandru
authors: Martin
authors: M
authors: Markowitz
authors: Christine
authors: C
authors: Armbruster
authors: Renate
authors: R
authors: Kunert
authors: Martha M
authors: MM
authors: Eibl
authors: Hermann
authors: H
authors: Katinger
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D000918:Antibody Specificity; D001780:Blood Coagulation Tests; D002308:Cardiolipins / Q000276:immunology; D002986:Clinical Trials as Topic; D003429:Cross Reactions; D004306:Dose-Response Relationship, Immunologic; D064420:Drug-Related Side Effects and Adverse Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015483:HIV Antibodies / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects* / Q000379:methods; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000276:immunology; D007231:Infant, Newborn; D008297:Male; D010718:Phosphatidylserines / Q000276:immunology; D011516:Prothrombin / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D002308:Cardiolipins; D015483:HIV Antibodies; D007155:Immunologic Factors; D010718:Phosphatidylserines; D011516:Prothrombin